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Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor, usually arises in
the setting of liver cirrhosis (LC), and has a poor prognosis. The recently discovered Th2-cytokine interleukin-33 (IL-33)
is a possible mediator in pancreatic and gastric carcinogeneses. IL-33 binds to its receptor and to soluble ST2 (sST2),
which thereby acts as a regulator. The role of IL-33 and sST2 in HCC has not been elucidated yet. METHODS: We
conducted a case-control study with 130 patients and 50 healthy controls (HCs). Sixty-five patients suffered from HCC
and 65 patients had LCwithout HCC.We assessed serum IL-33 and sST2 levels and their association with established
prognostic scores, liver function parameters, and overall survival (OS). RESULTS: No significant difference in IL-33
serum levels was found in HCC compared to LC and HCs. IL-33 levels did not correlate with OS, liver function param-
eters, the Model for End-Stage Liver Disease (MELD) score, or the Cancer of the Liver Italian Program (CLIP) score.
sST2 levels were significantly elevated in LC and HCC patients compared to HCs (P< .0001). Mean sST2 levels in LC
were higher than in HCC (P < .0001), but a significant association with OS was only observed in the HCC group (P =
.003). sST2 in HCC correlated with the CLIP score, the MELD score, and liver function parameters. CONCLUSION: In
the present study, the serum concentration of sST2 was associated with OS of HCC. Therefore, sST2 may be con-
sidered as a new prognostic marker in HCC and is worth further evaluation.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary malig-
nant liver tumor, usually arises in the setting of liver cirrhosis (LC),
and accounts for up to 70% to 85% of all primary liver cancers [1].
More than 700,000 cases are newly diagnosed each year with a high
incidence especially in Asian countries [2]. Patients with HCC often
present at an advanced stage of the disease leaving limited treatment
options due to underlying LC and a lack of effective systemic therapies.
Therefore, prognosis is poor with a median overall survival (OS) of
less than 1 year [3]. To the present day, prognosis in those patients
is mainly derived from different staging systems, e.g., the Barcelona
Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program
(CLIP), or Japan Integrated Scoring System [4]. New types of bio-
markers (e.g., des-γ-carboxy prothrombin, α-L-fucosidase, human
carbonyl reductase 2, tumor-specific growth factor, and hepatocyte
growth factor) have recently been under investigation [5]. Some of
them have shown good sensitivity in terms of early HCC detection
but failed to show a good correlation with prognosis. New prognostic
markers such as CXCL5, HMGB1, or vascular endothelial growth
factor receptor-1 (VEGFR-1) have not yet been established in clinical
routine [6–8]. Th1- and Th2-associated cytokines like interleukin-6
(IL-6) or IL-10 also play an important role since hepatic carcinogenesis
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is closely related to the host immune response and the tumor immune
surveillance [9,10].
IL-33 was discovered as a novel cytokine belonging to the IL-1 family
in 2005 [11]. It is expressed by various nonhematopoietic cells includ-
ing endothelial cells, fibroblasts, bronchial and epithelial cells, and
certain populations of immune cells, e.g., macrophages and dendritic
cells [12]. Currently, it is proposed that IL-33 is released upon cellular
necrosis as a 30-kDa molecule (full-length IL-33) and is processed into
less active forms of 20 to 22 kDa by caspase-3 and caspase-7 cleavage
[13–15]. IL-33 signaling is mediated by its receptor ST2 that exists in
a soluble form (sST2) and as a transmembrane receptor (ST2L). Bind-
ing to ST2L leads to activation of nuclear factor κB and mitogen-
activated protein kinase signaling pathways. sST2 is assumed to act as
a decoy receptor for IL-33 and thereby attenuates its biologic activity
[16,17]. In contrast to IL-1 and IL-18 triggering Th1/Th17 immune
responses, IL-33 mainly promotes Th2 cytokines such as IL-4, IL-5,
and IL-13 [11]. The role of the IL-33/ST2 axis has been extensively
studied in Th2-driven chronic inflammatory conditions such as asthma,
rheumatoid arthritis, allergic rhinitis, or inflammatory bowel disease.
The role of IL-33 and ST2 in terms of carcinogenesis and tumor pro-
gression is less well understood. It is known that IL-33 contributes
to alternative macrophage activation leading to recently described M2
polarization [18,19]. Tumor-associated macrophages are known to play
a relevant role in different types of solid tumors. Polarization towards
immune regulative M2 seems to be unfavorable since tumors are pro-
tected and escape immune surveillance. In an in vitro model, IL-33
has been described as a crucial mediator of inflammation-associated
pancreatic carcinogenesis [20]. Elevated levels of IL-33 have been de-
termined in sera and tumor tissue of gastric cancer patients and were
associated with prognostic markers such as depth of tumor invasion
[21]. In contrast to that, other authors have described IL-33 as a potent
inducer of anticancerogenic immunity leading to enhanced activation
of cytotoxic CD8+ cells [22]. ST2 levels were elevated in breast cancer
patients and associated with tumor progression and metastasis [23]. In
the field of hepatology, IL-33 has recently been identified as an impor-
tant factor contributing to liver injury caused by chronic hepatitis C
and is also associated with fibrosis in in vitro models [24].
However, the relation between IL-33 and sST2 serum levels and the
severity of disease and the survival of patients suffering from LC and of
patients suffering from cirrhosis and HCC has not been determined
yet. In the present study, we analyzed for the first time IL-33 and
sST2 serum levels in such patients and examined the association of
IL-33 and sST2 with severity and prognosis of liver disease in cirrhotic
patients with and without HCC.
Patients and Methods
Patients
Sixty-five patients suffering from LCwithHCC and 65 patients with
LC without HCC treated at the Department of Gastroenterology at
Johann Wolfgang Goethe University Hospital were included in the
study. Patients were matched one by one in a case-controlled manner.
This was a substudy of two case-control studies performed at theGoethe
University Hospital. Written informed consent was obtained from all
patients before inclusion in the study. The studies were approved by
the Ethics Committee of the Goethe University Hospital.
Patients with LC and HCC (HCC group). Sixty-five patients
with LC and recently diagnosed HCC who were admitted to our liver
unit between April 2009 and August 2011 were prospectively enrolled
in the present study. Inclusion criteria wereHCCdiagnosed on the basis
of histologic samples obtained from liver biopsies before study inclu-
sion or on the basis of morphologic/visual criteria according to current
American Association for the Study of Liver Diseases (AASLD) guide-
lines. When the diagnosis of HCC was confirmed by dynamic imaging,
two independent dynamic imaging techniques were used including
dynamic contrast-enhanced magnetic resonance imaging (MRI) or four-
phase computed tomography (CT), whereas arterial hypervascularity
and delayed or venous phase washout was obligatory for diagnosis.
Additionally, such patients received contrast-enhanced ultrasound
and/or lipiodol angiography. Patients were assigned to different BCLC
stages or CLIP scores on the basis of clinical examination, laboratory
tests, and CT/MRI or ultrasound findings. Exclusion criteria were
defined by an age below 18 years, former liver transplantation, ongoing
concomitant autoimmune disease including asthma and allergies, and a
history of cancer within the last 5 years other than HCC.
Patients with LC without HCC (LC group). Sixty-five patients
with LC who had been admitted to our liver unit from May 2009
to May 2010 were included in a comparison cohort and were individ-
ually matched to the HCC group according to age, sex, model for end-
stage liver disease (MELD) score, etiology of liver disease, and laboratory
values [C-reactive protein (CRP), sodium, creatinine, bilirubin, inter-
national normalized ratio (INR)]. Patients were included in the compar-
ison cohort when they had LC assessed by histopathologic examination
or pathognomonic results in abdominal ultrasound examination, transient
elastography, CT, or MRI. Exclusion criteria were an age below 18 years,
former liver transplantation, a history of cancer within the last 5 years,
and clinical or morphologic signs of HCC.
At the day of informed consent and enrollment of patients, blood
samples for further analysis were obtained and blood was also tested
for routine parameters of clinical chemistry.
Healthy controls (HC group). Sera of 50 individuals were collected
on a voluntarily basis. Individuals were free of any significant disease
including asthma and allergies, nonsmokers, and had no history of
concomitant liver disease.
Blood Sampling
Ten milliliters of peripheral blood was collected from each patient
at the time of study inclusion (heparinized serum tubes; Sarstedt,
Nümbrecht, Germany). The tube was immediately centrifuged at
3000g for 10 minutes to remove cellular components, aliquoted,
and then stored at −80°C until the date of experiments. Sera of the
50 healthy individuals were collected, centrifuged, aliquoted, and stored
in the same way.
Clinical Chemistry
Routine parameters of clinical chemistry were measured at the Cen-
tral Laboratory of the Goethe University Hospital.
Detection of IL-33 and sST2 by ELISA
The concentrations of IL-33 and sST2 in the sera of individual patients
and HCs were determined by ELISA. Commercially available human
IL-33 and sST2 ELISA kits were used according to the manufacturers’
instructions (R&D Systems, Minneapolis, MN). Sera of all patients
and HCs were subjected to analysis and the concentrations of serum
IL-33 and sST2 in individual samples were calculated according to
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the standard curve established by using the recombinant IL-33 and
sST2 provided. The detection limit of the IL-33 and sST2 ELISA kits
was 16 pg/ml and 1.6 pg/ml, respectively.
Statistical Analysis
Data were analyzed and compiled using the BiAS software for
windows (version 9.11; Epsilon-Verlag, Darmstadt, Germany), SPSS
version 20 (IBM, Chicago, IL), and GraphPad Prism 5 for Windows
(version 5; GraphPad Software, La Jolla, CA). The primary end point
of the study was OS. Death was considered as event. Follow-up time
was time until death or last contact to the patient. OS rates and sur-
vival curves were calculated for all patients using the Kaplan-Meier
model. Independent predictors of survival were determined with a
univariate and a multivariate Cox regression analysis using forward
stepwise (likelihood ratio) entry. The nonparametric Wilcoxon-Mann-
Whitney and Kruskal-Wallis tests were used to determine differences
between groups of patients. A Bonferroni correction was used whenmul-
tiple subgroup comparisons were performed. The data are expressed as
means ± SEM unless specified. P values < .05 were considered to be
significant. The correlation coefficient ρ was calculated by using the
Spearman correlation.
Results
A total of 130 patients were included in the study. Sixty-five of them
suffered from HCC and 65 had LC without HCC. Since the groups
were matched individually, no significant differences in terms of age,
sex, MELD, underlying etiology of liver disease, and laboratory values
were observed (Table 1). In 59 of 65 HCC patients, the diagnosis
of HCC was confirmed by histopathologic examination of biopsy
material, and in 6 of the 65 patients, HCC diagnosis was performed
on the basis of morphologic/visual criteria according to current AASLD
guidelines [25].
sST2 Levels Are Raised in Patients with HCC and LC
IL-33 and sST2 serum levels were assessed in patients with HCC
and LC and in a cohort of HC subjects. There was a tendency to higher
IL-33 levels in HCC in comparison to LC (1079.6 ± 310.1 vs 203.4 ±
49.95 pg/ml), but the difference was not statistically significant (P =
.41). The IL-33 levels in patients with LC did not differ from HCs
(203.4 ± 49.95 vs 218.6 ± 45.8 pg/ml, P = .51). Mean sST2 levels
in HCC were 741.6 ± 109.0 pg/ml compared to 1653.0 ± 228.2
pg/ml in LC (P < .0001). sST2 levels in both HCC and LC were
significantly higher than in HCs (38.5 ± 10.1 pg/ml, P < .0001). See
Table 2 and Figure 1 for details.
Levels of IL-33 and sST2 in Association with Tumor Stage
IL-33 levels in HCC patients at BCLC stage D were significantly
higher than at BCLC stage C (4163 ± 2329 vs 375.1 ± 300.8 pg/ml,
P = .01) and at BCLC stage B (4163 ± 2329 vs 1081 ± 460.4 pg/ml,
P = .01; Figure 2). The highest sST2 levels were found in BCLC
stage C and D patients (1345 ± 322.2 and 1355 ± 557 pg/ml, respec-
tively). sST2 levels in BCLC stage A (460.3 ± 121.5 pg/ml) and
B patients (476.0 ± 78.26 pg/ml) were significantly lower in compari-
son to BCLC stage C patients (P = .02 and P = .002; Figure 3).
Levels of IL-33 and sST2 in Accordance to Underlying
Liver Disease
Serum levels of IL-33 and sST2 were also analyzed in accordance
to the etiology of the underlying liver disease. Three subgroups con-
sisting of patients with chronic hepatitis B (HBV) or hepatitis C
(HCV) and alcohol-induced liver disease were compared. The analysis
revealed higher IL-33 concentrations in the HCV and alcohol groups
in comparison to the HBV group in HCC and LC patients. However,
neither in the HCC group nor in the LC group the differences were
statistically significant. A similar but again insignificant tendency was
obtained for the sST2 levels in the HCC and LC groups with higher
sST2 levels in the HCV and alcohol subgroups and lower levels in the
HBV group (Figure 4).
Correlation of IL-33 and sST2 with Liver
Function Parameters
To investigate the possible role of IL-33 and sST2 in necroinflamma-
tion and cell turnover, the correlation between IL-33 and sST2 levels
with surrogate markers of cell death, liver function, and established
prognostic scores in patients with HCC and LC without HCC was
analyzed. IL-33 levels did not correlate with liver enzymes [aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)], liver
synthesis (INR), α-fetoprotein (AFP), the MELD score, or the CLIP
score. In the HCC group, the sST2 serum concentration significantly
correlated with AFP, CRP, the MELD score, and the CLIP score. In
the LC group, sST2 was inversely correlated with IL-33 and positively
correlated with AST and INR (Table 3).
Survival Data
As sST2 levels correlated with parameters associated with survival
(MELD and CLIP scores), the relations between sST2 and IL-33 serum
Table 1. Patients’ Characteristics.
HCC Group LC Group P Value HCs
Number (n) 65 65 50
Male (n) 56 (86%) 61 (93.8%) 1.0 28 (56%)
Mean age (range) 64.4 (38–83) 62.4 (27–79) .31 35 (23–57)
Liver cirrhosis (n) 61 (93.8%) 65 (100%) 0 (0%)
HBV 9 (14.7%) 9 (14.7)
HCV 26 (42.6%) 28 (43.1%)
Alcohol 23 (37.7%) 33 (50.7%)
Others 7 (10.7%) 7 (10.7%)
HCC (n) 65 (100%) 0 (0%) 0 (0%)
BCLC A 9 (13.8%) NA
BCLC B 36 (55.4%) NA
BCLC C 17 (26.2%) NA
BCLC D 4 (6.2%) NA
MELD score (mean ± SD) 11.0 ± 3.96 11.8 ± 3.91 .08
CLIP score (mean ± SD) 3 ± 1.4 NA
AFP (ng/ml, mean ± SD) 4520 ± 1835 NA
Bilirubin (mg/dl) 1.94 ± 3.19 1.77 ± 1.73 .44
Creatinine (mg/dl) 1.0 ± 0.6 1.03 ± 0.42 .48
INR 1.23 ± 0.22 1.27 ± 0.22 .14
Sodium (mmol/l) 139.4 ± 4.82 138.7 ± 4.47 .23
CRP (mg/dl) 2.27 ± 3.6 1.35 ± 1.98 .44
NA, not applicable.
Table 2. IL-33 and sST2 Levels in HCC, LC, and HC.
HCC Group LC Group P Value HCs
IL-33
Mean ± SEM (pg/ml) 1079.6 ± 310.1 203.4 ± 49.95 NS 218.6 ± 45.8
sST2
Mean ± SEM (pg/ml) 741.6 ± 109.0 1653.0 ± 228.2 <.0001 38.5 ± 10.1
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levels and OS were assessed. Referring to the data obtained from HCs,
the highest sST2 value found in that group was used as a cutoff
(307 pg/ml). Kaplan-Meier analysis revealed a significant association
between the sST2 levels and OS in HCC patients. Mean OS was
928.1 days with low sST2 levels [±46.8 days, 95% confidence interval
(CI) = 836.3–1019.9] and 522.4 days with high sST2 levels (P = .003,
±77.6 days, 95% CI = 370.3–674.5). Survival curves for HCC
patients according to their sST2 levels are shown in Figure 5A. For
patients with LC, the same cutoff (307 pg/ml) was used and Kaplan-
Meier analysis was performed. However, although patients with LC
with low sST2 levels tended to show a better prognosis, the differ-
ence among both groups was not statistically significant (P = .262;
Figure 5B). Furthermore, there was no significant relation between
serum IL-33 levels and OS in the HCC and LC groups (P = .297
and P = .101, respectively).
As sST2 was significantly associated with OS in HCC, we sought to
determine association with OS independently from other parameters.
First, a univariate Cox regression analysis using sST2, age, gender, the
CLIP score, BCLC stage, CRP, AFP, ALT, and AST was performed.
The analysis showed that only low sST2 (P = .018, hazard ratio (HR) =
0.084, 95% CI = 0.011–0.654) and a low CLIP score (P = .005, HR =
0.210, 95% CI = 0.071–0.624) were associated with OS in HCC
patients. Additionally, a sex- and age-corrected multivariate analysis
with forward stepwise likelihood ratio with inclusion of the CLIP score,
AFP, CRP, ALT, and AST was performed. The analysis revealed that
only the sST2 levels (P = .021, HR = 0.088, 95% CI = 0.011–0.693)
and the CLIP score (P = .010, HR = 0.235, 95% CI = 0.077–0.711)
were independently associated with OS (Table 4).
IL-33/sST2 Ratio
IL-33 binds to the sST2 receptor, thereby mediating its function
as a regulator. Therefore, the potential bioactivity of free IL-33 was
determined by calculation of the IL-33/sST2 ratio for each patient.
The mean ratio found in HCs was significantly higher than in HCC
patients (149.2 ± 41.9 vs 32.61 ± 28.6, P < .0001) and in LC patients
(149.2 ± 41.9 vs 0.42 ± 0.13, P < .0001). The difference of the mean
Figure 1. Comparison of IL-33 and sST2 serum levels in HCC, LC, and HCs. IL-33 levels in HCC tended to be higher than in LC. sST2
levels in both LC and HCC patients were significantly higher than in HCs (P < .0001).
Figure 2. IL-33 levels in HCC according to BCLC stage. IL-33 levels
were significantly higher at BCLC stage D than at stage B or C.
Figure 3. sST2 levels according to BCLC stage. Significantly higher
levels of sST2 were observed at BCLC stage C.
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IL-33/sST2 ratio between HCC and LC indicated a higher amount
of unbound IL-33 in HCC patients, but the difference between those
two was not statistically significant.
Discussion
IL-33 is a recently identified cytokine with diverse and context-
dependent functions. IL-33 has been described as a potent inducer
of Th2 immune responses as well as “alarmin” cytokine released from
necrotic cells [26,27]. Together with its receptor ST2 that exists in a
soluble form sST2 and a transmembrane form ST2L, the influence
of the IL-33/ST2 axis reaches from protective to pathogenic in various
disease conditions. In dextran sodium sulfate (DSS)-induced chronic
colitis in mice, exogenously administered IL-33 has a protective effect
on the epithelial barrier, whereas exogenous administration in a liver
fibrosis model is pathogenic and leads to profibrotic switch of cytokine
production [24]. Little is known about the function of IL-33 and its
soluble receptor sST2 in patients with LC or HCC, two diseases with
different conditions regarding their clinical and immunologic basis. In
our work, we assessed for the first time IL-33 and sST2 serum concen-
trations in cirrhotic patients with and without HCC and compared it to
HCs. We found significantly higher sST2 levels in cirrhotic patients
with and without HCC in comparison to healthy subjects. Kaplan-
Meier analysis revealed a significant association between sST2 levels
and OS in patients suffering from HCC.
The finding of high sST2 levels in our patients with HCC is in line
with the data of Gillibert-Duplantier et al. showing elevated serum
concentrations of sST2 in patients with metastatic breast cancer [23].
High sST2 levels have also been found in malignant pleural effusions of
patients with lung cancer [28]. Furthermore, it has been demonstrated
that a lack of ST2 in ST−/− mice is associated with suppressed breast
cancer progression and metastasis, which was accompanied by en-
hanced cytotoxic activity of NK cells and increased systemic Th1/
Th17 cytokines [29]. Nevertheless, to the current date, it remains un-
clear whether sST2 is causally and directly involved in carcinogenesis
or whether it is to be seen as a marker of concomitant inflammation
Figure 4. (A and B) Comparison of IL-33 and sST2 levels according to underlying liver disease. HCV patients had slightly higher IL-33
and sST2 levels than other patients in both the HCC and LC groups. Differences were not significant.
Table 3. Correlations of sST2 with Liver Function Parameters, CLIP Score, MELD Score,
and IL-33.
HCC Group LC Group
ρ P Value ρ P Value
AFP 0.32 .008 NA NA
CRP 0.51 <.0001 0.06 NS
CLIP 0.47 <.0001 NA NA
MELD 0.33 .007 0.17 NS
AST 0.30 .01 0.27 .031
INR 0.05 NS 0.31 .01
IL-33 0.03 NS −0.26 .035
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or tissue injury. Evidence for that arises from elevated levels of sST2,
which are also found in nontumor conditions, e.g., allergy, atopy, mul-
tiple sclerosis, inflammatory bowel diseases, and recently even in cardio-
vascular disease [30–32]. The significant correlation of the sST2 serum
concentration with the levels of AST and CRP in our study indicates
that sST2 is associated with liver injury and (hepatic) cell death as well
as the systemic inflammatory response. The association with systemic
inflammation is supported by other publications dealing with sST2 in
different disease settings. The Dallas Heart Study revealed a significant
association of sST2 with markers of inflammation; furthermore, sST2
was highly associated with all-cause mortality and cardiovascular mor-
tality [33]. Another study showed elevated levels of sST2 in diabetic
patients with critical limb ischemia, again predicting mortality in those
patients [34]. Correspondingly, our study also showed a significant
elevation of sST2 in LC, primarily a nontumor condition. This fact
must be addressed considering the different cytokine environment in
LC and HCC patients. Several publications clearly demonstrated an
up-regulation of Th1 cytokines like IL-1β, IL-2, or tumor necrosis
factor α (TNF-α) in patients with LC [9,35,36]. For many different tu-
mor types, e.g., gastric cancer [37,38], pancreatic cancer [39], or colorec-
tal cancer [40–42], a shift toward a Th2-dominant immune response has
been shown. A local Th2 cytokine skewing in HCC was seen by Budhu
et al. and was associated with a metastatic phenotype [35]. It is also
known that ST2 is induced in a proinflammatory environment by
tumor necrosis factor α, IL-6, and IL-1β [43–45].We therefore hypoth-
esize that high levels of sST2 in the sera of LC patients are to be seen in
the wake of a proinflammatory cytokine environment of LC patients,
thus supporting the above-mentioned hypothesis of inflammation.
However, despite higher levels of sST2 in LC, differences in OS for
Figure 5. (A) Survival curve for HCC patients according to sST2 serum levels. Patients with high sST2 levels (cutoff = 307 pg/ml) had a
significantly worse OS (P = .003). (B) Survival curve for LC patients according to sST2 serum levels. OS of LC patients with high sST2
levels tended to be worse, but the difference was not statistically significant (cutoff = 307 pg/ml, P = .262).
Table 4. Univariate and Multivariate Analyses of Parameters Associated with Overall Survival.
Parameter Univariate Analysis Multivariate Analysis
HR 95% CI P Value HR 95% CI P Value
Low sST2 0.084 0.011–0.654 .018 0.088 0.011–0.693 .021
Male gender 0.495 0.139–1.768 .279
Age < 67 years 1.832 0.575–5.841 .306
CLIP score ≤ 3 0.210 0.071–0.624 .005 0.235 0.077–0.711 .010
BCLC stage A 1.246 0.340–4.566 .740
Normal CRP 0.446 0.100–1.994 .290
AFP ≤ 400 ng/ml 0.424 0.146–1.232 .115
ALT ≤ 50 U/l 0.258 0.059–1.138 .074
AST ≤ 50 U/l 0.037 0.000–12.746 .269
Low sST2, sST2 serum level ≤ 307 pg/ml; normal CRP, C-reactive protein ≤ 0.5 mg/dl.
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those patients were not significant in contrast to the association of OS
and sST2 levels in HCC patients.
Referring to the previously addressed context-dependent functions
of IL-33, levels observed in the HCC group of our study tended to be
higher in comparison to both LC patients and healthy individuals.
The IL-33/sST2 ratio in HCC indicated a higher amount of unbound
IL-33 in those patients compared to LC patients. Considering IL-33
as an “alarmin” similar to HMGB1 [26], elevated levels in HCC are
possibly caused by its release from necrotic tumor cells, thus induc-
ing antitumoral immunity by recruiting CD4+ and CD8+ cytotoxic
lymphocytes as well as interferon-γ (IFN-γ) producing NK cells
[17,22]. Neutralization of IL-33 by its soluble receptor sST2 may then
lead to attenuation of antitumoral immunity. If this provides an expla-
nation for the negative prognostic impact of sST2 in HCC is unsure
and has yet to be demonstrated.
In conclusion, this is the first study to show a significant correlation
of survival in HCC patients with serum levels of the IL-33 receptor
sST2. Our data suggest an important role of sST2 in HCC, whereas
the implicit function—promotor of carcinogenesis or reflection of
systemic inflammation—remains to be clarified. Further research will
be needed to clearly elucidate the source, regulation, secretion, and
degradation of IL-33 and ST2 in HCC and LC and to evaluate their
potential as prognostic markers.
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